Shaanxi Meibang Pharmaceutical Group Co., Ltd. (605033.SS)
CNY 12.67
(-0.63%)
CNY 12.67
(-0.63%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 699.02 Million CNY | -22.85% |
| 2022 | 906.04 Million CNY | 7.54% |
| 2021 | 842.49 Million CNY | 48.19% |
| 2020 | 568.51 Million CNY | 10.24% |
| 2019 | 515.7 Million CNY | 17.59% |
| 2018 | 438.55 Million CNY | 3.93% |
| 2017 | 421.95 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 195.97 Million CNY | -37.2% |
| 2024 Q3 | 111.92 Million CNY | -42.25% |
| 2024 Q1 | 312.08 Million CNY | 114.65% |
| 2023 Q2 | 131.44 Million CNY | -61.87% |
| 2023 FY | 699.02 Million CNY | -22.85% |
| 2023 Q4 | 145.39 Million CNY | 87.63% |
| 2023 Q3 | 77.48 Million CNY | -41.05% |
| 2023 Q1 | 344.7 Million CNY | 55.26% |
| 2022 Q3 | 66.37 Million CNY | -48.98% |
| 2022 Q2 | 130.09 Million CNY | -73.32% |
| 2022 Q1 | 487.55 Million CNY | 66.94% |
| 2022 FY | 906.04 Million CNY | 7.54% |
| 2022 Q4 | 222.02 Million CNY | 234.49% |
| 2021 FY | 842.49 Million CNY | 48.19% |
| 2021 Q4 | 292.05 Million CNY | 293.31% |
| 2021 Q3 | 74.25 Million CNY | -63.17% |
| 2021 Q2 | 201.6 Million CNY | -26.58% |
| 2021 Q1 | 274.57 Million CNY | 77.01% |
| 2020 FY | 568.51 Million CNY | 10.24% |
| 2020 Q4 | 155.11 Million CNY | 223.22% |
| 2020 Q3 | 47.99 Million CNY | -67.48% |
| 2020 Q2 | 147.58 Million CNY | -32.24% |
| 2020 Q1 | 217.82 Million CNY | 0.0% |
| 2019 FY | 515.7 Million CNY | 17.59% |
| 2018 FY | 438.55 Million CNY | 3.93% |
| 2017 FY | 421.95 Million CNY | 0.0% |